Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet β-cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet β-cell function, independent of glycemic control (Diabetes Research and Clinical Practice)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Our results demonstrated that EMPA, mainly acting on SGLT2, prevented DNA methylation changes induced by high glucose and provided evidence of a new mechanism by which SGLT2i can exert cardio-beneficial effects (Cardiovascular Diabetology)
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes (The Lancet Diabetes & Endocrinology)
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Empagliflozin is the latest SGLT2i drug to show proven benefits in both hyperglycemia, CV disease, heart failure, and now CKD progression. The new EMPA-KIDNEY data proves that it provides benefits in patients with and without diabetes and can be used in those with eGFR down to 20 mL/min/1.73m (Therapeutics and Clinical Risk Management)
Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
Our findings in individuals recently diagnosed with diabetes provide new evidence associating higher serum NFL levels with DSPN and peripheral nerve dysfunction. The present study advocates NFL as a potential biomarker for DSPN (Diabetologia)
Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort
This study showed differential and independent prospective associations between manifestations of early kidney damage in diabetes and several CVD subtypes, suggesting that regular monitoring of both kidney function measures may help to identify individuals at higher risk of specific cardiovascular events (Diabetologia)
The association of diabetes status and bone mineral density among US adults: evidence from NHANES 2005–2018
Using NHANES data from 2005 to 2018, we found that patients with abnormal glucose metabolism had increased bone mineral density (BMC Endocrine Disorders)
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes
Our results showed that more patients with iDegLira had HbA1c less than 7% and these combination had better effect on weight loss. There was no difference observed in FPG and PPG, lipid profile and rate of hypoglycaemia (BMC Endocrine Disorders)
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA, and CARMELINA: assessment of a novel staging system for type 2 diabetes
Applying the DSS across T2D clinical trial populations with different CV risk revealed significantly increased risk for ACM and CV death with higher DSS stage. The DSS may benefit from assessment in other T2D populations and with evaluation of the impact of additional outcomes, such as heart failure (Diabetes, Obesity and Metabolism)
Meta-Analysis of Head-to-Head Clinical trials Comparing Incretin-Based Glucose-Lowering Medications and Basal Insulin – An Update Including Recently Developed GLP-1 Receptor Agonists and the GIP/GLP-1 Receptor Co-Agonist Tirzepatide
In particular, recently introduced, highly effective IBGLM were superior over basal insulin treatment, reinforcing the recommendation that IBGLM should be considered as the first injectable treatment for most patients with type 2 diabetes (Diabetes, Obesity and Metabolism)
Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials
SGLT2i reduce risk of renal and HF outcomes for all eGFR categories. The greatest benefits in terms of kidney protection may be achieved by early initiation of SGLT2i in people with preserved eGFR. Greatest risk reduction for HF outcomes is observed in people with lower eGFR values (Diabetes, Obesity and Metabolism)
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial
Glycaemic control and hypoglycaemia worry improved significantly up to 24 months after switching from isCGM without alerts to rtCGM with alerts, supporting the use of rtCGM in the care of adults with type 1 diabetes (The Lancet Diabetes & Endocrinology)
The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
In this global post-marketing study, none of the adverse events was reported more frequently among older adults. Our findings provide reassurance regarding SGLT2i treatment in older adults, although careful monitoring is warranted (Cardiovascular Diabetology)
Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care
Multiple examples of therapeutic inertia were identified, including first prescription at HbA1c levels considerably above target and failure to escalate to optimal doses even with evidence of suboptimal metabolic control. A substantial proportion of patients therefore did not achieve optimal HbA1c targets (Diabetes, Obesity and Metabolism)
Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study
Both low (< 6.0% [42 mmol/mol]) and high (≥ 8.0% [64 mmol/mol]) levels of glycaemic control are associated with increased all-cause mortality and diabetes-related macrovascular complications. Glycaemic variability is independently associated with increased risk for these outcomes. Therefore, patients with stable glycaemic level of 6– 8% (42– 64mmol/mol) are at lowest risk of all-cause mortality and diabetes-related macrovascular complications (Clinical Epidemiology)
Identifying diabetogenic drugs using real world healthcare databases: a Danish and Australian symmetry analysis
We identified 70 drug-diabetes associations, of which 27 were classified as hitherto unknown. Further studies evaluating the hypotheses generated by this work are needed, particularly for the signal for digitalis glycosides (Diabetes, Obesity and Metabolism)
Bariatric-metabolic surgery for NHS patients with type 2 diabetes in the United Kingdom National Bariatric Surgery Registry
NHS bariatric-metabolic surgery is used for people with T2DM much later in the disease process when it is less effective. National guidance on bariatric-metabolic surgery and data from multiple RCTs have had little impact on clinical practice (Diabetic Medicine)
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
Dapagliflozin reduced kidney and cardiovascular events in patients with type 2 diabetes and CKD across baseline GLT class or classes in combination (Diabetes Care)
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
Dapagliflozin reduced the risk for hospitalization for any cause in patients with CKD with and without type 2 diabetes (Annals of Internal Medicine)
A Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial
A microbiome-targeting nutritional formula significantly improved cT2-DDAS and HbA1c, suggesting the potential for prebiotic fiber as a complement to lifestyle and/or pharmaceutical interventions for managing type 2 diabetes (Diabetes, Obesity and Metabolism)
- 1
- 2
- 3
- …
- 250
- Next Page »
Glycosmedia is also available as an App: